| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | MENTIONED | LOW | Rob Black Show Afternoon podcast 9-23-26 |
Rob described Novo Nordisk as the other major GLP-1 supplier, with approximately 39% market share in his comparison with Lilly. [audio] | -0.1% | — | — |
| 2026-09-22 | MENTIONED | LOW | Rob Black Show Markets Near High As Oil Falls |
Novo Nordisk was identified as an established obesity-drug competitor facing Roche's prospective entry. [audio] | -2.8% | — | — |
| 2026-09-21 | WATCH | MEDIUM | Rob Black Show Stocks Rise As Oil Prices Ease |
Novo's 2030 plan disappointed investors because of slowing growth, semaglutide dependence, and Eli Lilly's lead despite a large drug pipeline. [audio] | -2.7% | — | — |
| 2026-09-14 | WATCH | MEDIUM | Rob Black Show Major Shakeup In Artificial Intelligence Amid Safety Concerns |
Novo was discussed as trying to rebuild growth after losing obesity-drug share to Eli Lilly. [audio] | -8.4% | — | — |
| 2026-08-27 | SELL | HIGH | Rob Black Show Nvidia Revenue Outlook Lifts Chip Stocks |
Described as one of the great fallen stars, roughly 70% below its June 2024 peak, with Deutsche Bank downgrading to sell on slower growth, obesity-drug competition and a looming patent cliff. [audio] | +2.7% | -16.1% | — |
| 2026-08-13 | HOLD | MEDIUM | Rob Black Show More Encouraging Inflation Data |
Novo Nordisk was raised as a possible value and GLP-1 comeback play, but Rob preferred Lilly for diversification. [audio] | +0.0% | -6.6% | — |
| 2026-08-12 | SELL | HIGH | Rob Black Show Tame Inflation Data |
Berenberg downgraded the Wegovy maker to hold from buy, arguing it must prove it can maintain an edge in oral weight loss drugs against Eli Lilly. [audio] | +1.5% | -6.0% | — |
| 2026-08-05 | MENTIONED | HIGH | Rob Black Show Afternoon podcast 8-5-26 |
Novo Nordisk is Lilly's key competitor with Ozempic and Wegovy, and investors are comparing Lilly's oral GLP-1 launch to Novo's oral Wegovy rollout. [audio] | +4.2% | +6.0% | — |
| 2026-07-24 | BUY | HIGH | Rob Black Show Broader Market Rebounded |
Novo Nordisk is discussed as a leader in weight loss drugs; expected to benefit from FDA decisions and maintain pricing power. [audio] | -3.4% | -2.9% | — |
| 2026-07-23 | SELL | HIGH | Rob Black Show Markets Lower As Tech Disappoints |
Host describes Novo Nordisk as wounded and left behind; expects sales decline and underperformance versus Lilly. [audio] | +7.1% | -1.7% | — |
| 2026-06-22 | MENTIONED | LOW | Rob Black Show Afternoon podcast 6-22-26 |
Novo Nordisk's Wagovia and Ozempic mentioned as medicines requiring strict refrigeration. [audio] | +5.4% | +5.0% | -4.5% |
| 2026-06-22 | MENTIONED | LOW | Rob Black Show Declines In Technology Stocks |
Novo Nordisk's GLP-1 medicines Wagovi and Ozempic are discussed for their need for temperature control. [audio] | +5.4% | +5.0% | -4.5% |
| 2026-06-12 | BUY | HIGH | Rob Black Show Afternoon podcast 6-12-26 |
Novo Nordisk sales rose more than 30% recently, reflecting growing demand for its weight loss drug Wagovi. [audio] | -1.6% | +12.8% | +1.6% |
| 2026-06-08 | MENTIONED | MEDIUM | Rob Black Show Stocks Rebound From Friday Rout |
Novo Nordisk's semaglutide compared to Lilly's weight loss drugs. [audio] | +7.1% | +19.2% | +15.1% |
| 2026-05-20 | BUY | MEDIUM | Rob Black Show Afternoon podcast 5-20-26 |
Host expresses bullish sentiment on Novo Nordisk (and Eli Lilly) for their GLP-1 drugs that will save lives and extend longevity. [audio] | -1.1% | -4.2% | +2.7% |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Stocks Slide Under Pressure From Higher Rates |
Novo Nordisk is listed as one of the pharmaceutical companies offering discounts on TrumpRx. [audio] | -0.2% | -2.4% | +2.7% |
| 2026-05-13 | MENTIONED | MEDIUM | Rob Black Show Mixed Markets As Inflation Jumps |
Discussed partnering with OpenAI to identify drug candidates using AI. [audio] | -4.3% | -6.8% | +0.2% |
| 2026-05-12 | BUY | MEDIUM | Rob Black Show Stocks Move After High Inflation Reading |
Speaker highlights Novo Nordisk as a major company behind GLP-1s with Wagovi Pills doing great. [audio] | -5.8% | -6.5% | +1.6% |
| 2026-05-07 | MENTIONED | MEDIUM | Rob Black Show Oil Continues Pullback |
Novo Nordisk's GLP-1 pill sales are discussed. [audio] | +0.0% | -6.2% | -2.8% |
| 2026-05-06 | BUY | HIGH | Rob Black Show Earnings Jump |
Shares jumped 7% on new obesity pill numbers and raised full-year guidance. [audio] | +2.9% | -6.1% | -3.2% |
| 2026-04-21 | MENTIONED | MEDIUM | Rob Black Show Afternoon podcast 4-21-26 |
Novo Nordisk mentioned in the context of the pharmaceutical sector. [audio] | +4.4% | +12.6% | +25.8% |